Business
Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results
ALISO VIEJO, Calif., February 17, 2026--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025. Key highlights include:
About this update from Glaukos Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2774,"height":518,"url":"https://media.zenfs.com/en/business-wire.com/a8eb61b057ba8c702f79b84e95d3447d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dDxHcxWHwEQB8xgheCmGug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE3OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a8eb61b057ba8c702f79b84e95d3447d","width":960,"height":179},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/dcFPi629FIS8WHH1QcewMw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00NDg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/a8eb61b057ba8c702f79b84e95d3447d","width":1200,"height":224}},"lazy":false},{"type":"text","content":"ALISO VIEJO, Calif., February 17, 2026--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025. Key highlights include:","length":369,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Record net sales of $143.1 million in Q4 2025 increased 36% year-over-year on a reported basis and 34% year-over-year on a constant currency basis.","length":147,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Glaucoma record net sales of $119.2 million in Q4 2025 increased 42% year-over-year.","length":84,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"U.S. Glaucoma record net sales of $86.4 million in Q4 2025 increased 53% year-over-year.","length":88,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Net sales of $507.4 million in 2025 increased 32% year-over-year.","length":65,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Reaffirmed 2026 net sales guidance of $600 million to $620 million.","length":67,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":451,"olType":false},{"type":"text","content":""Our record fourth quarter results cap off a highly successful year of global execution across our key commercial and development initiatives, leaving us well positioned to sustain our strong growth momentum in 2026 and beyond driven by two transformational growth ...